Insys Therapeutics Inc (INSY)
$0.29 0.00 (0.00%)
19:32 EDT INSY Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 21.49M
PE Ratio -0.09
Volume (Avg. Vol.)
Day's Range 0.29 - 0.29
52-Week Range -
Dividend & Yield N/A (N/A)
INSY Stock Predictions, Articles, and Insys Therapeutics Inc News
- From InvestorPlace
- From the Web
Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher on approval for the company's First Day motions,
The Insys Therapeutics bankruptcy news coming out on Monday about it filing for Chapter 11 has INSY stock tanking hard today.
It's not a great reason in and of itself to buy CGC stock , but Canopy Growth does have an overlooked presence in the medical cannabis arena.
Pharmaceutical stocks have been on the rebound and many are raising their prices this year. What does that mean for business?
Marijuana stocks have endured some of the worst from the October fallout, but a few American names have substantial potential.
Marijuana stocks like Cronos, Cannabis Sativa and Canopy Growth are just a handful of the names worth a closer look here.
In the first six months of the year, the FDA grants approval to 17 new treatments. Compare Brokers....
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
For marijuana stocks like GWPH, ZYNE and INSY, a federal crackdown on marijuana legalization laws is no big deal.
These Trump stocks have gained so much that traders should take profits now: DryShips (DRYS), SAExploration (SAEX) and Insys (INSY).
If marijuana initiatives perform well on Election Day, opioid pharma stocks such as MYL, DEPO and INSY could be the big losers.
While most investors are focused on who becomes the next president, marijuana stocks are watching legalization votes in nine key states.
The overall ratings of 41 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
INSY is flying high after posting 9% gains on the strength of Insys Therapeutics' now-FDA-approved drug, Syndros.